Aclaris Therapeutics ACRS Insider Ownership

Updated Oct 10, 2026

Over the trailing 12 months, ACRS insiders sold $1.36 million worth of shares (300K shares) in open-market trades, with no open-market purchases.

• Braden Michael Leonard (10% owner) sold the most Aclaris Therapeutics stock on the open market over the past 12 months, $1.36 million (300K shares), most recently on April 23, 2026.
• Outside the open market, Aclaris Therapeutics insiders acquired 413.75K shares through option exercises and conversions and gave up 145.82K shares to cover taxes or exercise prices over the past 12 months.
• Per Business Quant data, Aclaris Therapeutics insiders hold 17.6Mn shares in total based on their latest Form 4 filings, up 0.14% from 17.57Mn shares at the end of Q2 2026 and up 0.06% from 17.59Mn shares at the end of Q3 2025.
• Indirect holdings, through trusts, partnerships, family members and other entities, make up 81.73% (14.38Mn shares) of Aclaris Therapeutics' insider total, with the other 18.27% (3.21Mn shares) held directly.
• Per Business Quant, 14 insiders of ACRS hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• ACRS's largest insider holders by reported holdings are Braden Michael Leonard (10% owner, 13.95Mn shares), Neal Walker (CEO, 1.54Mn shares) and Anand Mehra (Director, 726.4K shares).
• Braden Michael Leonard holds 79.27% of the combined insider position in Aclaris Therapeutics.
• Institutional holders reported 83.47% of Aclaris Therapeutics' outstanding shares for Q2 2026; insiders' latest Form 4 filings put their stake at about 12.33%, and other investors, including the public, hold the remaining 4.20%.
• Over the past 12 months, 13 insiders reported transactions in Aclaris Therapeutics stock in 27 Form 4 filings.
• These insider figures for Aclaris Therapeutics are based on Form 4 filings through August 4, 2026.